Keltai, M.

patient treatment study infarction treatment e ffect intervention investigator effect trial region baseline epti fibatide europe month america heart di fferences event function measurement perindopril percutaneou placebo finition fibatide outcome latin america artery death fference group ace inhibition events committee brachial artery pursuit fi ve times inhibition patient outcome creatine treatment bene fit analysis heart failure result difference mortality change committee bene fit brachial disease eur heart j treatment e ffects end-point reduction angiotensin artery disease 6 months signi center europa limit failure dysfunction inhibitor latin improvement cardiovasc variation 36 months elevation fmd measurement table perindopril group syndrome value enalapril period diameter kinase event rate